TCGX Acquisition Corp.
TCGX Acquisition Corp. is based in Palo Alto, California. The company focuses on combining with one or more businesses through transactions that may involve a merger, amalgamation, share exchange, share purchase, asset acquisition, reorganization or a similar arrangement.
No SEC Form 4 filings for $TCGX in the last 30 days.
See all $TCGX insider activity →TriGemX Bio and TCGX Acquisition Corp. (TCGX) filed a confidential draft registration statement with the SEC for their proposed merger. The deal would take TriGemX public on Nasdaq under the ticker TGEM, with completion expected in Q1 2027. TriGemX's drug candidate, elismetrep, is in Phase 3 trials for migraine treatment, with results anticipated in mid-2027.
TriGemX Bio, a biotech firm developing migraine treatment elismetrep, plans to go public via a merger with TCGX Acquisition Corp. (TCGX). The deal, expected to close in Q1 2027, would list the combined company on Nasdaq under 'TGEM'. Elismetrep is in Phase 3 trials, with results anticipated in mid-2027. The merger is subject to regulatory approvals and shareholder votes.
TCGX Acquisition will merge with TriGemX in a SPAC deal valued at $361M, targeting Q1 2027. The transaction includes a $160M PIPE at $10.00 per share. Closing is subject to shareholder approvals and Nasdaq listing. According to the company, the merger aims to take TriGemX public.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning TCGX (TCGX Acquisition Corp.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent TCGX coverage spans mergers & acquisitions, corporate actions and financial news.
The filing signals progress toward closing the merger, likely supporting TCGX's share price.
The SPAC merger announcement introduces dilution and execution risk, likely weighing on TCGX's share price.
The merger adds a new public biotech to TCGX's portfolio and injects $160M cash, likely driving the SPAC's share price higher.
The SPAC deal will dilute existing shareholders but creates a new biotech listed as TGEM, offering upside if the Phase 3 trial succeeds.
Fund close and regional office build suggest increased deal flow and capital availability for Asia biotech investments, but it is not a direct public-market catalyst.
AlphAI scores every news story that mentions TCGX with an AI model for sentiment and relevance, and aggregates insider trades from TCGX Acquisition Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TriGemX Bio and TCGX Acquisition Corp. (TCGX) filed a confidential draft registration statement with the SEC for their proposed merger. The deal would take TriGemX public on Nasdaq under the ticker TGEM, with completion expected in Q1 2027. TriGemX's drug candidate, elismetrep, is in Phase 3 trials for migraine treatment, with results anticipated in mid-2027.
1 min readTriGemX Bio, a biotech firm developing migraine treatment elismetrep, plans to go public via a merger with TCGX Acquisition Corp. (TCGX). The deal, expected to close in Q1 2027, would list the combined company on Nasdaq under 'TGEM'. Elismetrep is in Phase 3 trials, with results anticipated in mid-2027. The merger is subject to regulatory approvals and shareholder votes.
2 min readTCGX Acquisition will merge with TriGemX in a SPAC deal valued at $361M, targeting Q1 2027. The transaction includes a $160M PIPE at $10.00 per share. Closing is subject to shareholder approvals and Nasdaq listing. According to the company, the merger aims to take TriGemX public.
2 min readTCGX Acquisition Corp. (TCGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine Transaction Includes Concurrent $160 million Private Investment in Public Equity
2 min readTCGX closed a $600M Asia Life Sciences Fund I, backed by institutional investors, to invest in biotech across Asia. Biohaven licensed its IgG degrader portfolio to Ono for $200M, including $80M upfront. Roche partnered with Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases.
6 min read
.webp%253Fdisable%253Dupscale%2526width%253D1200%2526height%253D630%2526fit%253Dcrop&w=384&q=75)